436 related articles for article (PubMed ID: 19344187)
21. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia.
Kreitman RJ; Wilson WH; Bergeron K; Raggio M; Stetler-Stevenson M; FitzGerald DJ; Pastan I
N Engl J Med; 2001 Jul; 345(4):241-7. PubMed ID: 11474661
[TBL] [Abstract][Full Text] [Related]
22. Recombinant single-chain and disulfide-stabilized Fv-immunotoxins that cause complete regression of a human colon cancer xenograft in nude mice.
Reiter Y; Wright AF; Tonge DW; Pastan I
Int J Cancer; 1996 Jul; 67(1):113-23. PubMed ID: 8690511
[TBL] [Abstract][Full Text] [Related]
23. In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma.
Onda M; Wang QC; Guo HF; Cheung NK; Pastan I
Cancer Res; 2004 Feb; 64(4):1419-24. PubMed ID: 14973056
[TBL] [Abstract][Full Text] [Related]
24. HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity.
Bang S; Nagata S; Onda M; Kreitman RJ; Pastan I
Clin Cancer Res; 2005 Feb; 11(4):1545-50. PubMed ID: 15746059
[TBL] [Abstract][Full Text] [Related]
25. Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox.
Kreitman RJ; Pastan I
Clin Cancer Res; 2011 Oct; 17(20):6398-405. PubMed ID: 22003067
[TBL] [Abstract][Full Text] [Related]
26. New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells.
Du X; Ho M; Pastan I
J Immunother; 2007 Sep; 30(6):607-13. PubMed ID: 17667524
[TBL] [Abstract][Full Text] [Related]
27. Recombinant immunotoxins for treating cancer.
FitzGerald DJ; Kreitman R; Wilson W; Squires D; Pastan I
Int J Med Microbiol; 2004 Apr; 293(7-8):577-82. PubMed ID: 15149034
[TBL] [Abstract][Full Text] [Related]
28. Rational design of low immunogenic anti CD25 recombinant immunotoxin for T cell malignancies by elimination of T cell epitopes in PE38.
Mazor R; Kaplan G; Park D; Jang Y; Lee F; Kreitman R; Pastan I
Cell Immunol; 2017 Mar; 313():59-66. PubMed ID: 28087047
[TBL] [Abstract][Full Text] [Related]
29. Targeting Pseudomonas exotoxin to hematologic malignancies.
Kreitman RJ; Pastan I
Semin Cancer Biol; 1995 Oct; 6(5):297-306. PubMed ID: 8562907
[TBL] [Abstract][Full Text] [Related]
30. Responses in refractory hairy cell leukemia to a recombinant immunotoxin.
Kreitman RJ; Wilson WH; Robbins D; Margulies I; Stetler-Stevenson M; Waldmann TA; Pastan I
Blood; 1999 Nov; 94(10):3340-8. PubMed ID: 10552943
[TBL] [Abstract][Full Text] [Related]
31. Improving the
Kaplan G; Mazor R; Lee F; Jang Y; Leshem Y; Pastan I
Mol Cancer Ther; 2018 Jul; 17(7):1486-1493. PubMed ID: 29695631
[TBL] [Abstract][Full Text] [Related]
32. Anti-Tac(Fab)-PE40, a recombinant double-chain immunotoxin which kills interleukin-2-receptor-bearing cells and induces complete remission in an in vivo tumor model.
Kreitman RJ; Chang CN; Hudson DV; Queen C; Bailon P; Pastan I
Int J Cancer; 1994 Jun; 57(6):856-64. PubMed ID: 8206679
[TBL] [Abstract][Full Text] [Related]
33. Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.
Salvatore G; Beers R; Margulies I; Kreitman RJ; Pastan I
Clin Cancer Res; 2002 Apr; 8(4):995-1002. PubMed ID: 11948105
[TBL] [Abstract][Full Text] [Related]
34. Accumulation of a recombinant immunotoxin in a tumor in vivo: fewer than 1000 molecules per cell are sufficient for complete responses.
Kreitman RJ; Pastan I
Cancer Res; 1998 Mar; 58(5):968-75. PubMed ID: 9500458
[TBL] [Abstract][Full Text] [Related]
35. Recombinant antibody fragments and immunotoxin fusions for cancer therapy.
Brinkmann U
In Vivo; 2000; 14(1):21-7. PubMed ID: 10757057
[TBL] [Abstract][Full Text] [Related]
36. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies.
Kreitman RJ; Squires DR; Stetler-Stevenson M; Noel P; FitzGerald DJ; Wilson WH; Pastan I
J Clin Oncol; 2005 Sep; 23(27):6719-29. PubMed ID: 16061911
[TBL] [Abstract][Full Text] [Related]
37. Recombinant toxins containing the variable domains of the anti-Tac monoclonal antibody to the interleukin-2 receptor kill malignant cells from patients with chronic lymphocytic leukemia.
Kreitman RJ; Chaudhary VK; Kozak RW; FitzGerald DJ; Waldman TA; Pastan I
Blood; 1992 Nov; 80(9):2344-52. PubMed ID: 1421405
[TBL] [Abstract][Full Text] [Related]
38. Cytotoxicity of antiosteosarcoma recombinant immunotoxins composed of TP-3 Fv fragments and a truncated Pseudomonas exotoxin A.
Onda M; Olafsen T; Tsutsumi Y; Bruland OS; Pastan I
J Immunother; 2001; 24(2):144-50. PubMed ID: 11265772
[TBL] [Abstract][Full Text] [Related]
39. Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activity.
Onda M; Nagata S; Tsutsumi Y; Vincent JJ; Wang Q; Kreitman RJ; Lee B; Pastan I
Cancer Res; 2001 Jul; 61(13):5070-7. PubMed ID: 11431343
[TBL] [Abstract][Full Text] [Related]
40. Humanized CD7 nanobody-based immunotoxins exhibit promising anti-T-cell acute lymphoblastic leukemia potential.
Yu Y; Li J; Zhu X; Tang X; Bao Y; Sun X; Huang Y; Tian F; Liu X; Yang L
Int J Nanomedicine; 2017; 12():1969-1983. PubMed ID: 28331319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]